•  
  •  
  •  
  •  

2025-09-28 03:00:21

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Anand Rayons Ltd receives approval for STAPII trademark
  • IRFC extends funding support to PVUNL for INR 3,388.51 crore
  • Zaggle Prepaid Ocean Services Ltd enters into agreement with IDFC First Bank Ltd
  • PNG Jewellers expands National Footprint, Celebrates Lucknow's Cultural Legacy with Maiden Store Launch
  • Interarch strengthens presence in Multi-Storey Steel Buildings with new plant in Attivaram, Andhra Pradesh

Keywords Selected:  GlenmarkPharmaceuticals

Stock Report

  • Glenmark Strengthens Oncology Portfolio with Hengrui's HER2 Targeting ADC For Multiple Regions
  • Glenmark Pharma arm receives upfront payment of $700 Mn from AbbVie
  • Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial
  • Ichnos Glenmark Innovation announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie
  • Ichnos Glenmark Innovation and AbbVie announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
  • Glenmark Pharmaceuticals Launches TEVIMBRA® in India
  • U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA
  • Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA® in India to Advance Treatment of Hematological Malignancies
  • Ichnos Glenmark Innovation receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
  • Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets
  • Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)
  • Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
  • Glenmark Pharma expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India
  • Glenmark Therapeutics Inc., USA launches Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful - OTC
  • Glenmark Pharmaceuticals Inc., USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial
  • Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules
  • Glenmark Pharmaceuticals Inc., USA launches Lacosamide Oral Solution, 10 mg/mL
  • Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004%
  • U.S. FDA inspection at Glenmark Pharmaceuticals Ltd's Facility at Chhatrapati Sambhaji Nagar, India
  • Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% OTC
  • Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg
  • Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg - OTC

Latest Post

  • Anand Rayons Ltd receives approval for STAPII trademark
  • IRFC extends funding support to PVUNL for INR 3,388.51 crore
  • Zaggle Prepaid Ocean Services Ltd enters into agreement with IDFC First Bank Ltd
  • PNG Jewellers expands National Footprint, Celebrates Lucknow's Cultural Legacy with Maiden Store Launch
  • Interarch strengthens presence in Multi-Storey Steel Buildings with new plant in Attivaram, Andhra Pradesh


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024